Carisma Therapeutics Inc.
CARM Healthcare Biotechnology
Carisma Therapeutics Inc.’s revenue for fiscal 2024 (year ended December 2024) was $19.6 million, up 31.6% from fiscal 2023. In the quarter to September 2025, revenue grew 392.0%, EPS grew 445.2% and free cash flow grew 114.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow CARM
Carisma Therapeutics Inc. (CARM) EV/Sales
As of 16 October 2026, Carisma Therapeutics Inc. (CARM) trades at a EV/Sales of 0.0×. Over the past ten years it has ranged from −21.6× (February 2016) to 108× (May 2015); the current reading is higher than 20% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2023 | 1.2× | 20.75% |
| FY2022 | 1.0× | — |
| FY2021 | −0.4× | — |
| FY2020 | 2.5× | 977.40% |
| FY2017 | 0.2× | (57.82%) |
| FY2016 | 0.6× | (98.21%) |
| FY2015 | 31.2× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2025 | 0.2× | (41.89%) |
| Mar 2025 | 0.3× | — |
| Dec 2024 | 0.0× | — |
| Sep 2024 | 0.7× | (51.64%) |
| 23 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CARM Carisma Therapeutics Inc. | 0.0× |
| NEXI NexImmune, Inc. compare | n/m |
| PTIX Atrinsic Inc. compare | n/m |
| GNPX GENPREX compare | n/m |
| ARTL Artelo Biosciences, Inc. compare | n/m |
| ABPO Abpro Holdings Inc. compare | n/m |
| MLEC Moolec Science SA compare | 0.1× |
| ITRMF Iterum Therapeutics PLC compare | 24.4× |
| TRVN Trevena, Inc. compare | 35.0× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)